Tue, Sep 23, 2014, 10:29 AM EDT - U.S. Markets close in 5 hrs 31 mins


% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

marsala1234 48 posts  |  Last Activity: Sep 18, 2014 5:44 PM Member since: Jan 31, 2003
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I'm going to give an honest opinion that some in the crowd may disagree with! This comes after extensive discussion with alot of docs and my own analysis.
    I'll start with a few assumptions:
    -Physician acceptance of CG will be a big driver in it's success
    -Physicians are becoming more cost conscious of the things they do than they were in the past (cost effectiveness is a bigger part of the education process)
    -Some physicians will see a cost of $500-$600 every 3 years as excessive compared to FIT (without understanding the big advantages of CG over FIT as they won't understand the nuances that some on this board do). Perception is reality for some.

    Therefore, I am actually thinking that the "sweet spot" of great margins combined with physician acceptance and use might be in the $350-$450 range. (averages out to around $133/year with q 3 year use).
    I am actually hoping for this range as an investor and a doc as giving the best long term returns.

    Long timers - What do you think? Crazy wish?

  • marsala1234 marsala1234 Sep 6, 2014 5:02 PM Flag

    Ssteph - You are correct there is no screening recommendations for average risk patients. High risk patients can be screened by:
    Endoscopic ultrasound (EUS), a minimally invasive imaging test that uses an endoscope (thin, flexible tube) to evaluate the pancreas for lesions or early cancers. If suspicious lesions are present, doctors obtain tissue biopsies during the same procedure.
    Magnetic resonance cholangiopancreatography (MRCP), a type of magnetic resonance imaging (MRI) test that focuses on the pancreas and bile duct.
    Computed tomography (CT) scans, another imaging test that can show some types of suspicious lesions. Here, our experts can offer high-resolution 3-D pancreatic CT imaging, which produces better, more detailed diagnostic images.
    Endoscopic retrograde cholangiopancreatography (ERCP), a test that combines the use of endoscopes and X-rays to visualize the pancreas and biliary tree. Biopsies can also be performed during ERCP.

    I would guess you would have to examine stool of patients with various stages of Pan-c and determine the proper markers and cutoffs like they did with Cologuard. (This is already happening). You might get approval to sell this to high risk patients while a prospective randomized control study of high risk patients without known Pan -c is in progress. This type of study would likely take several years since Pan-c is much less common than colon ca. I imagine one or a combination of the above screening tools would be used to try and catch the cancer as early as possible.

  • Reply to

    "Homie don't do dat"

    by u_fail_again Sep 3, 2014 2:33 PM
    marsala1234 marsala1234 Sep 3, 2014 4:49 PM Flag

    Scorekeeper - I think you meant to say there were only 8 African Americans with a diagnosis of Colon Cancer.
    There were 1,000 AA's enrolled in the study or 10.7% of the Deep C patients.

  • Reply to

    Colon Cancer Alliance Cologuard FAQ

    by chuckles_head Aug 27, 2014 11:32 AM
    marsala1234 marsala1234 Aug 27, 2014 12:53 PM Flag

    steph "Are informed consent forms used with FIT?"

  • marsala1234 marsala1234 Aug 27, 2014 12:09 AM Flag

    pillprep - instead of always mentioning just the GI fee in the colonoscopy, why don't you mention the anesthesia fee and the facility fee and the biopsy/pathology fees. The average mcare colonoscopy COST is $800-1000 and much more for commercial insurers. Why do you ignore that only 16/100 people who get CG will need a colonoscopy?

  • Reply to

    Cologuard and FDA

    by catalystforfreedom Aug 25, 2014 11:46 PM
    marsala1234 marsala1234 Aug 26, 2014 11:17 AM Flag

    Jim - The reason you want to replace colonoscopy is because it is very expensive, very uncomfortable, very time consuming and potentially dangerous and 50% of Americans WON'T do it.
    The reason we keep comparing it to pap smears is to show that even a less sensitive test if done in short intervals with a very slow growing cancer can virtually ELIMINATE cancer deaths as it has done with cervical cancer. Cologuard is very similar, only better than a pap smear. Done every 3 year CG will likely detect nearly 99% of all cancers in a curable stage. Make sense?

  • marsala1234 marsala1234 Aug 25, 2014 11:58 PM Flag

    You are correct Sstephan. As long as fobt/fit are in the guidelines they can be used by physicians without concern. BUT, Double Contrast Barium enemas are still on the American Cancer Society list of approved screening tests - and I haven't seen one of them done in 10 years!. It will take some time but CG will eventually get the 3 magic words in non-invasive screening - STANDARD OF CARE.

  • Reply to

    Why General Doctors will love EXAS

    by fivepayne Aug 25, 2014 2:26 PM
    marsala1234 marsala1234 Aug 25, 2014 2:39 PM Flag

    Primary care docs won't get anything from this except maybe a visit to discuss the test.

  • Reply to

    Pill Prep Exposé

    by chuckles_head Aug 23, 2014 9:16 PM
    marsala1234 marsala1234 Aug 24, 2014 11:14 PM Flag

    pillprep- you said " they (Aetna) aren't going to pay $600 for a test that will lead to a colonoscopy if they can just pay $1000 for the colonoscopy and be done with it." You act like every Cologuard leads to a colonoscopy! Under the worst circumstance of 13% false +'s, and 3-4% true positives, that means that 83-84/100 patients who get Cologuard will NOT have to have a colonoscopy. That is a big win for patients and insurers.
    As a doc, think of why cervical cancer has been almost eliminated in the US (it is the #1 cause of cancer deaths in women in developing countries). The Pap smear has a sensitivity of of 50-60% but due to interval screening can catch almost all cervical cancers in the early cancer stage or precancer. We could do colposcopy (the colonoscopy equivalent) on every patient and it is much less invasive and expensive than a colonoscopy. However, we have figured out that we could eliminate cervical cancer with testing every 3 years with a simpler screening test.
    We can do the same with Cologuard. Wouldn't that be great. Now I agree CG is much more expensive than a Pap. I would be happy with $300/test because it will still be a financial success and I think many more will be done at that price here and in other countries.
    I do agree with you that I would not use it on high risk patients unless they refused a colonoscopy until further data comes out.

  • Reply to

    they are playing games with this now

    by diejour_44 Aug 22, 2014 1:41 PM
    marsala1234 marsala1234 Aug 22, 2014 1:53 PM Flag

    Of course no insurers are covering the test yet! It just got FDA approve and insurers wait on CMS coverage decisions before moving forward. (see my prior message on CMS and insurer coverage). Coverage will come after CMS decision and will take a little time - but it will get covered.

  • Reply to

    Summary of CMS predictions

    by biotechinvestornow Aug 21, 2014 4:49 PM
    marsala1234 marsala1234 Aug 21, 2014 5:01 PM Flag

    Bio - put me in at $399.99

  • New article out today: Some excerpts from the article:
    "IBD is associated with increased colorectal cancer risk. In fact, 10%-15% of colorectal cancer-related deaths occur in the patients with colitis. Risk factors for colorectal cancer in patients with IBD include longer duration of disease, disease severity, the presence of primary sclerosing cholangitis, and less use of 5-ASA products.

    We typically monitor patients with IBD according to duration and extent of their disease. We were taught that they should be monitored with random biopsies and also biopsies of targeted lesions. At a minimum, at least 2 biopsies should be taken 10 cm apart, with a minimum of 33 biopsies per patient. It is very time-consuming, and if you also take targeted biopsies, the cost in terms of processing fees begins to add up.
    Frank Farraye,[7] an expert in chromoendoscopy, suggests that we should start training programs for chromoendoscopy and continue to do random biopsies, but use indigo carmine as well to become familiar with it.
    What should you be doing? You should be developing a chromoendoscopy program for all of your patients with IBD. There is no question that, when coupled with high-definition endoscopy, this is going to be a standard of care."

    Can't wait to see the results of the IBD study by EXACT to see if a simple stool test might be better than 33 biopsies per patient! or chromoendoscopy. This could be very big and I'm sure is not in any projections yet.

  • Reply to

    Not trying to bash but....

    by azzholee22 Aug 19, 2014 8:12 PM
    marsala1234 marsala1234 Aug 20, 2014 6:05 PM Flag

    JH - glad you're so excited about the container but:

    "false positives are less than a colonoscopy" isn't quite accurate!

    Colonoscopy was the standard on which the false +'s are based so it's not possible to have a higher false + rates with colonoscopy.

  • marsala1234 marsala1234 Aug 19, 2014 5:20 PM Flag

    just mentioned on CNBC, guy adami calls it a 25 stock

  • Obviously, it's crucial for coverage of those on Mcare. My question has been will private insurers follow suit and how quickly as I don't think most people will pay $599 out of pocket if their insurer says no coverage.
    Found some interesting quotes by healthcare experts when researching this topic:

    "The biggest and most intense battle within the U.S. health care system during the past two decades has been over two inter-related questions: (1) who will control the manner in which medical care is paid for and, (2) how much will it cost? � [T]he private sector neither initiated this battle nor provided the critical innovation that transformed health care in the U.S. Instead, it was Medicare�s transition to a prospective payment system (PPS) that both triggered and repeatedly intensified the economic restructuring of the U.S. health care system� Roughly akin to Wal-Mart, in terms of purchasing power, the key to Medicare�s role as the leading catalyst for change in the U.S. health care system is the program�s immense size and influence. As the single largest individual buyer of health care and the �first mover� in the annual payment game between those who provide medical care and those who pay for it, "Medicare invariably drives the behavior of both medical providers and private payers".� [Emphasis added]

    Jacob Hacker reiterates that point:

    �Over the last two decades, moreover, Medicare has increasingly emphasized improved payment methods and rigorous reviews of technology and treatment, and it has made increasing investments in quality monitoring and improvement. Revealingly, private plans generally use the public Medicare plan�s criteria for covering treatments as their standard of medical necessity, and they have adopted many of Medicare�s innovations in payment methods

    Not sure how fast this occurs but it certainly gives me more confidence of complete coverage of Cologuard in the not too distant future.

  • Reply to

    Pricing of Cologuard is $599

    by chuckles_head Aug 16, 2014 9:12 PM
    marsala1234 marsala1234 Aug 18, 2014 3:43 PM Flag

    Dave - Let's say - just for the purpose of discussion- that Mcare reimburses at $400 (1/3 discount to $599).
    what would you expect private insurers to reimburse at? Thanks.

  • marsala1234 by marsala1234 Aug 15, 2014 10:00 PM Flag

    You're right Taxlawyer Just got the Email about the NYT ad and a link to asking your Dr. about Cologuard

    Headline was:

    Cologuard is convenient and easy to use.

    Not wasting any time.

  • Reply to

    Switch from Colonoscopy to Cologuard

    by mad_1957 Aug 15, 2014 10:16 AM
    marsala1234 marsala1234 Aug 15, 2014 2:35 PM Flag

    Oldguy - good points. I don't think they can advertise this as a colonoscopy replacement or have the sales rep push it as such. I guess in more subtle ways they can show how this truly is comparable to a scope when used at the approved 3 year interval vs. just targeting the FIT user. You guys might be right in that the patient may drive the demand and the docs will follow. Will be fascinating to see the uptake over the next year.

  • Reply to

    Switch from Colonoscopy to Cologuard

    by mad_1957 Aug 15, 2014 10:16 AM
    marsala1234 marsala1234 Aug 15, 2014 1:36 PM Flag

    Steph - I hope you are correct, but unfortunately patients can't order the test (and get it paid for by insurance). The docs will have to be on board.

  • Reply to

    Switch from Colonoscopy to Cologuard

    by mad_1957 Aug 15, 2014 10:16 AM
    marsala1234 marsala1234 Aug 15, 2014 1:25 PM Flag

    I agree this is the key question. The move from FIT to Cologuard is an easy mental switch and clinically will make sense for most docs. The move from nothing to Cologuard shouldn't be a tough switch for most patients.
    The move from colonoscopy to Cologuard will be a bigger sell. Conroy has always stated Exas wants to replace FIT and not colonoscopies. Most of us realize that was BS and a PR tool not to offend the GI community too much. BUT, I think their marketing approach and education of sales staff will have to divert from the company line of Cologuard as a replacement for FIT and really explain to Docs that due to the programmatic sensitivity of the test it really does rival the efficacy of colonoscopy. If KC doesn't take the gloves off a bit on this issue the uptake will be slower.
    I was VERY relieved that the FDA statement made no mention of Cologuard as being a replacement for FOBT/FIT and it was a general cancer screen. My big fear was some type of statement that would have recommended that this replace FIT but was not a subsititute for screening colonoscopy.

1.2194-0.0306(-2.45%)10:28 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.